Announced details
Prevention and treatment of osteoarthritis
株式会社PrimRNA, a subsidiary of NANO MRNA株式会社, is conducting a Phase 1 clinical trial of RUNX1 mRNA in Australia, while our company is conducting joint research and development with Professor Itaka Keiji (位髙 啓史).
A research group led by Professor Itaka Keiji (位髙 啓史) at the Osaka University Research Institute for Infectious Diseases. Other information, including location, representative, business activities, capital and year established, is Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
The international scientific journal Science Advances and the website of the Osaka University Research Institute for Infectious Diseases
| Item | Details |
|---|---|
| Names of Products / Services Covered | RUNX1 mRNA, Col9 mRNA, Polymeric micelles |
| Counterparty | Osaka University Research Institute for Infectious Diseases, and the research group led by Professor Itaka Keiji (位髙 啓史) |
| Counterparty overview | A research group led by Professor Itaka Keiji (位髙 啓史) at the Osaka University Research Institute for Infectious Diseases. Other information, including location, representative, business activities, capital and year established, is Not disclosed. |
| Relationship with the Company | 株式会社PrimRNA, a subsidiary of NANO MRNA株式会社, is conducting a Phase 1 clinical trial of RUNX1 mRNA in Australia, while our company is conducting joint research and development with Professor Itaka Keiji (位髙 啓史). |
| Applicable area | Prevention and treatment of osteoarthritis |
| Source | The international scientific journal Science Advances and the website of the Osaka University Research Institute for Infectious Diseases |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Research findings by the group led by Professor Itaka Keiji (位髙 啓史) were published in the international scientific journal Science Advances. The publication explains that Col9 mRNA and RUNX1 mRNA suppress the progression of osteoarthritis through different mechanisms.